Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects

Diabetes Research and Clinical Practice

Volumn 38, Issue 1, 1997, Pages 41-51

  Foot, E A ^a   Eastmond, R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alcohol; In vitro; Pharmacodynamics; Pharmacokinetics; Troglitazone

Indexed keywords

ALCOHOL; C PEPTIDE; CREATININE; GLUCOSE; HYDROCORTISONE; INSULIN; LIPID; PLACEBO; PROINSULIN; TROGLITAZONE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HYPOGLYCEMIA; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CHROMANS; CREATININE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHANOL; FASTING; FEMALE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PROINSULIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0030774765     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(97)00082-X     Document Type: Article

References (22)

1. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
2. Sironi A.M., Vichi S., Gastaldelli A.et al. Effects of troglitazone on insulin sensitivity and cardiovascular risk factors (CVRF) in NIDDM. Diabetes. 45(suppl 2):1996;A680.
3. S. Kumar, A.J.M. Boulton, H. Beck-Nielsen et al., for the Troglitazone Study Group, Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients, Diabetologia 39 (1996) 701-709.
4. K. Levin, P. Thye-Ronn, E. Foot, H. Beck-Nielsen, Metabolic effects of troglitazone in NIDDM patients, Endocrinol. Metab. (in press).
5. J.C.N. Correa, J. Hilsted, D. Eckland, M. Starkie, S. Lettis, M. Young, for the troglitazone study group, Investigation of twice- or three-times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non insulin dependent diabetes mellitus, Eur. J. Clin. Res. 9 (1997) 151-165.
6. M. Leutenegger, L. Sacca, C. Alderton, D. Eckland, S. Lettis, for the troglitazone study group, Investigation of the optimal dose regimen for troglitazone: a double-blind, placebo-controlled, parallel group study of troglitazone 10, 30, 100 and 200 mg once daily in NIDDM. Curr. Ther. Res. (in press).
7. Tulokas S., Pelkonen R., Haapa E., Koshinen L., Koivula T. Alcohol with dinner reduces blood glucose next morning in type 2 diabetic patients. Diabetologia. 33:1990;A133.
8. Nikkila E.A., Taskinen M.R. Ethanol-induced alterations of glucose tolerance, post-glucose hypoglycemia and insulin secretion in normal, obese and diabetic subjects. Diabetes. 24:1975;933-943.
9. Madison L., Lochner A., Wulff J. Ethanol induced hypoglycemia: mechanism of suppression of hepatic gluconeogenesis. Diabetes. 16:1967;252-258.
10. Puhakainen I., Koivosto V.A., Yki-Jarvinen H. No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients. Diabetes. 40:1991;1319-1327.
11. Young M.A., Robinson C.E., DeVoy M.A.B., Minton N.A. The influence of food on the pharmacokinetics of GR92132X, a thiazolidinedione, in healthy subjects. Br. J. Clin. Pharmacol. 37:1994;482P.
12. White J.R., Hartman J., Campbell R.K. Drug interactions in diabetic patients. Drug Interactions. 93:1993;131-139.
13. Bell D.S.H. Alcohol and the NIDDM patient. Diabetes Care. 19:1996;509-513.
14. Koivisto V.A., Tulokas S., Toivonen M., Haapa E., Pelkonen R. Alcohol with a meal has no adverse effects on postprandial glucose homeostasis in diabetic patients. Diabetes Care. 16:1993;1612-1614.
15. Tulokas S., Pelkonen R., Haapa E., Koskinen L., Kiovula T. Alcohol with dinner reduces blood glucose next morning in type 2 diabetic patients. Diabetologia. 33:1990;A133.
16. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl. J. Med. 33:1994;1188-1193.
17. Nagi D.K., Hendra T.J., Ryle A.J.et al. The relationship of concentrations of insulin, intact proinsulin and des 31, 32 proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 33:1990;532-537.
18. Davies M.J., Metcalf J., Gray I.P., Day J.L., Hales C.N. Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus. Diabetes Med. 10:1993;305-312.
19. Eckland D.J.A., Williams Z.V., Foot E.A. Troglitazone improves glycaemia but does not increase the risk of hypoglycaemia following alcohol in diet-treated NIDDM subjects. Diabetologia. 39:1996;A233.
20. Hillson R.M., Hockaday T.D.R. Chlorpropamide-alcohol flush: a critical appraisal. Diabetologia. 26:1984;6-11.
21. Hartling S.G., Faber O.K., Wegmann M.-L., Wahlin-Boll E., Melander A. Interaction of ethanol and glipizide in humans. Diabetes Care. 10:1987;683-686.
22. Dubas T.C., Johnson W.J. Metformin-induced lactic acidosis: potentiation by ethanol. Res. Comm. Chem. Pathol. Pharmacol. 33:1981;21-31.